New Zealand markets open in 5 hours 36 minutes

Acorda Therapeutics, Inc. (CDG.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
0.78500.0000 (0.00%)
As of 08:02AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 799.66k
Enterprise value 172.38M
Trailing P/E 5.31
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.01
Price/book (mrq)0.29
Enterprise value/revenue 1.62
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.73
52-week change 3-94.23%
S&P500 52-week change 328.04%
52-week high 315.9000
52-week low 30.7850
50-day moving average 34.1290
200-day moving average 310.4032

Share statistics

Avg vol (3-month) 3112
Avg vol (10-day) 3N/A
Shares outstanding 51.24M
Implied shares outstanding 61.33M
Float 81.23M
% held by insiders 10.64%
% held by institutions 113.93%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 305 Jun 2023

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -214.95%
Operating margin (ttm)3.90%

Management effectiveness

Return on assets (ttm)-5.77%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)117.63M
Revenue per share (ttm)94.71
Quarterly revenue growth (yoy)20.70%
Gross profit (ttm)N/A
EBITDA 8.4M
Net income avi to common (ttm)-252.85M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)29.98M
Total cash per share (mrq)24.14
Total debt (mrq)190.9M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.33
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-13.98M
Levered free cash flow (ttm)20.14M